Results
Emcure Pharmaceuticals FY26 Revenue Crosses $1 Billion
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with unmodified audit opinions.
Recommended a final dividend of ₹3.60 per share (36% on face va
